Anbio Biotechnology Dossier
Qualitative Analysis
Business overview
Anbio Biotechnology is a global medical technology company specializing in the development, manufacturing, and provision of in vitro diagnostics (IVD) products. Founded in 2021 and headquartered in Frankfurt am Main, Germany, the company aims to revolutionize the diagnostics landscape by personalizing and decentralizing diagnostic solutions. Anbio's extensive portfolio spans multiple core technology platforms, including Lateral Flow Immunoassay (LFIA), Fluorescence Immunoassay (FIA), Chemiluminescence Immunoassay (ChLIA), Loop-mediated Isothermal Amplification (LAMP), Dry Chemistry, and Real-Time Polymerase Chain Reaction (RT-PCR). Its products cater to diverse diagnostic needs across over-the-counter (OTC) utilization, point-of-care (POCT) settings, and laboratory applications, detecting biomarkers associated with infectious diseases, oncology, cardiology, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding the company's global sales and distribution network across human and veterinary healthcare markets. This includes active participation in major international exhibitions (such as EuroMedLab 2025 in Brussels, AVA Conference 2025 in Sydney, and ACMTT 2025 in Bangkok) to secure new distribution partners, research collaborators, and strategic investors.
Expected impact: Aims to establish a stronger commercial presence in over 100 countries and bridge the gap between centralized laboratories and immediate site-of-care testing.
Pivoting from respiratory-dominated testing to a diversified, high-margin diagnostic portfolio. This includes launching the AP-100 Ultra-Fast PCR system (a 15-minute extraction-free molecular platform) and expanding the assay menu to include tuberculosis (TB), human papillomavirus (HPV), and Chikungunya tests.
Expected impact: Improves gross margins (which reached 87.2% in late 2025) and drives long-term organic growth by targeting high-margin clinical and point-of-care segments.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations